Table 3 Sensitivity analysis
Outcome | Polymorphism | Comparison | All studies | MD (95%CI) | I2 | Sensitivity analysis | Results | ||
|---|---|---|---|---|---|---|---|---|---|
No. Studies/ participant | No. Studies/ participant | MD 95%CI | I2 | ||||||
No. of oocytes retrieved | AMH (rs10407022) | TT versus GG/GT | 6/1739 | −0.19 (−1.29, 0.91) | 81% | a 5/1580 | −0.82 (− 1.55, − 0.08) | 52% | Became significant |
TT versus GG | 3/792 | 0.25 (−2.70, 3.21) | 93% | a 2/687 | −1.44 (−2.05, −0.83) | 0% | Became significant | ||
TT versus GT | 3/1199 | −0.27 (−1.66, 1.12) | 88% | a 2/1052 | −1.03 (− 1.87, − 0.19) | 70% | Became significant | ||
GG versus TT/GT | 3/1335 | −0.42 (− 0.2.69, 1.85) | 90% | a 2/1176 | 0.71 (0.06, 1.53) | 0% | Became significant | ||
AMHR (rs2002555) | AA versus GG/AG | 5/1614 | 0.01 (−0.81,0.83) | 66% | b 4/979 | 0.44 (−0.15, 1.02) | 0% | Not affected | |
AA versus GG | 3/969 | 0.32 (−1.34, 1.99) | 73% | b 2/509 | −0.53 (− 1.85, 0.79) | 0% | Not affected | ||
AA versus AG | 4/1587 | −0.41 (−1.31, 0.48) | 67% | c 3/1056 | −0.92 (−1.42, − 0.42) | 0% | Became significant | ||
GG versus AA/AG | 3/1342 | −0.36 (−2.24, 1.53) | 80% | b 2/707 | 0.58 (−0.70, 1.87) | 0% | Not affected | ||
Gn dosage | AMHR (rs2002555) | AA versus GG/AG | 4/1230 | −13.25 (−58.41, 32.47) | 63% | c 3/682 | −53.36 (−146.58, 39.86) | 44% | Not affected |
Stimulation duration | AMHR (rs2002555) | AA versus GG/AG | 3/907 | 2.81 (−4.51, 10.13) | 75% | b 2/270 | −0.27 (−0.86, 0.31) | 66% | Not affected |